LB may be particularly useful in the treatment of CRC patients to identify recurrence (e.g., RAS mutation testing to detect the emergence of treatment resistance associated with anti-EGFR therapy), and for early detection of cancer in defined subpopulations, such as those at high risk for CRC [34]. This evidence concerns the gene EGFR and colorectal carcinoma.